Market Overview

UPDATE: Piper Jaffray Raises PT to $32 on AmSurg; Long-Term Outlook Positive

Related AMSG
Benzinga's Top Initiations
KeyBanc Initiates Amsurg At Buy

Piper Jaffray maintained AmSurg (NASDAQ: AMSG) with a Neutral rating and raised the price target from $30.00 to $32.00.

Piper Jaffray commented, "We expect AMSG to trade down on mixed Q4 results and FY13 EPS guidance that was lower than Street estimates. Q4 revenues beat, while EPS missed Street expectations due to higher than expected interest expense relative to our model. While FY13 revenue guidance was fine, EPS was lower than expected. AMSG did see a slight uptick in GI procedures due to colon cancer screening and same-center growth of 3% was better than anticipated. We believe the overall environment remains stable and management noted hospitals are proactively reaching out to the company regarding partnership opportunities, which is a long-term positive."

AmSurg closed at $31.26 on Monday.

Latest Ratings for AMSG

DateFirmActionFromTo
Sep 2014Deutsche BankMaintainsBuy
Sep 2014KeyBancInitiates Coverage onBuy
Aug 2014CitigroupMaintainsBuy

View More Analyst Ratings for AMSG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMSG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters